U.S. Cannabinoids Market Size, Share & Trends Analysis Report By Product (Tetrahydrocannabinol (THC), Cannabidiol (CBD), Cannabigerol (CBG), Cannabichromene (CBC); Cannabinol (CBN)), And Segment Forecasts, 2022 - 2030
This report can be delivered to the clients within 3 Business Days
U.S. Cannabinoids Market Growth & Trends
The U.S. cannabinoids market size is expected to reach USD 60.4 billion by 2030 and is expected to expand at a CAGR of 16.2% over the forecast period, according to a new report by Grand View Research, Inc. Growing awareness regarding the health benefits provided by cannabinoids and the rising number of new players in the market, leading to expansion in the availability of products are fueling the growth. In addition, increasing acceptance and adoption of cannabis and cannabinoid-based treatments among consumers and medical professionals over the antibiotics treatment is further anticipated to boost the market growth in the forthcoming years.
Furthermore, changing perception and attitude toward cannabis products is further bolstering revenue growth. For instance, a 2020 article published in Cannabis products and research conducted by IRI & BDSA signified changing perceptions of consumers towards cannabis. The consumers were classified into three categories, namely consumers, acceptors, and rejectors. As per the research, around 33% of the population were acceptors and 36% were current consumers. In addition, mainstream acceptance increased by 10% in the past two years. Such instances signify the growing potential of the market soon.
In 2021, based on product, the cannabidiol (CBD) segment dominated the market with a revenue share of 27.2%. This growth is attributed to various factors, such as the rising consumption of CBD-based products in sports nutrition, health and wellness, cosmetics, and other fields. Furthermore, companies are trying to diversify their product portfolio into various forms for catering to a larger and growing consumer pool. It will help in improving the product visibility and penetration to newer customer segments.
In addition, players are constantly undertaking strategic initiatives, such as partnerships, collaborations, product launches, and much more to expand their revenue share and presence. For instance, in 2020, Marijuana Company of America, Inc. announced its mutual strategic investment and collaboration with Cannabis Global, Inc. This will help the company in gaining a foothold in the growing CBD market. In addition, this collaboration is also aimed at expanding the presence of both companies by leveraging the favorable resources of both companies.
The pandemic of COVID-19 has drastically impacted the overall cannabis industry, thereby impacting the U.S. market for cannabinoids. Supply chain disruption was one of the key factors that hampered the market during the pandemic. For instance, according to an article published in 2021 in Supply and Demand Chain Executive, disruption in the manufacturing, production, and distribution of cannabis and cannabinoid-based products led to shortages during the peak months of the pandemic. It also led to incurring additional costs for specialized transportation and/or distribution, thereby hampering the growth.
Other key factors that created obstacles during the pandemic include nationwide lockdown, panic buying of products, and price fluctuation. However, since the situation is heading towards normalcy, the adoption and demand for cannabinoid products are anticipated to increase.
U.S. Cannabinoids Market Report Highlights
U.S. Cannabinoids Market Growth & Trends
The U.S. cannabinoids market size is expected to reach USD 60.4 billion by 2030 and is expected to expand at a CAGR of 16.2% over the forecast period, according to a new report by Grand View Research, Inc. Growing awareness regarding the health benefits provided by cannabinoids and the rising number of new players in the market, leading to expansion in the availability of products are fueling the growth. In addition, increasing acceptance and adoption of cannabis and cannabinoid-based treatments among consumers and medical professionals over the antibiotics treatment is further anticipated to boost the market growth in the forthcoming years.
Furthermore, changing perception and attitude toward cannabis products is further bolstering revenue growth. For instance, a 2020 article published in Cannabis products and research conducted by IRI & BDSA signified changing perceptions of consumers towards cannabis. The consumers were classified into three categories, namely consumers, acceptors, and rejectors. As per the research, around 33% of the population were acceptors and 36% were current consumers. In addition, mainstream acceptance increased by 10% in the past two years. Such instances signify the growing potential of the market soon.
In 2021, based on product, the cannabidiol (CBD) segment dominated the market with a revenue share of 27.2%. This growth is attributed to various factors, such as the rising consumption of CBD-based products in sports nutrition, health and wellness, cosmetics, and other fields. Furthermore, companies are trying to diversify their product portfolio into various forms for catering to a larger and growing consumer pool. It will help in improving the product visibility and penetration to newer customer segments.
In addition, players are constantly undertaking strategic initiatives, such as partnerships, collaborations, product launches, and much more to expand their revenue share and presence. For instance, in 2020, Marijuana Company of America, Inc. announced its mutual strategic investment and collaboration with Cannabis Global, Inc. This will help the company in gaining a foothold in the growing CBD market. In addition, this collaboration is also aimed at expanding the presence of both companies by leveraging the favorable resources of both companies.
The pandemic of COVID-19 has drastically impacted the overall cannabis industry, thereby impacting the U.S. market for cannabinoids. Supply chain disruption was one of the key factors that hampered the market during the pandemic. For instance, according to an article published in 2021 in Supply and Demand Chain Executive, disruption in the manufacturing, production, and distribution of cannabis and cannabinoid-based products led to shortages during the peak months of the pandemic. It also led to incurring additional costs for specialized transportation and/or distribution, thereby hampering the growth.
Other key factors that created obstacles during the pandemic include nationwide lockdown, panic buying of products, and price fluctuation. However, since the situation is heading towards normalcy, the adoption and demand for cannabinoid products are anticipated to increase.
U.S. Cannabinoids Market Report Highlights
- The market size is projected to be valued at USD 60.4 billion by 2030, owing to increasing awareness regarding cannabinoids, their health benefits, and the growing use of cannabinoids
- Cannabidiol (CBD) dominated with the highest revenue share in 2021, owing to the rising consumption of CBD-based products in sports nutrition, health and wellness, cosmetics, and other fields
- CBGA products are expected to expand at the fastest CAGR over the forecast period owing to potential health benefits provided by CBGA in various health conditions
CHAPTER 1 METHODOLOGY AND SCOPE
1.1 Market Segmentation and Scope
1.2 Market Definition
1.3 Research Methodology
1.3.1 Information Procurement
1.3.1.1 Purchased Database
1.3.1.2 Gvr’s Internal Database
1.3.2 Primary Research
1.4 Research Scope And Assumptions
1.5 List To Data Sources
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Market Outlook
CHAPTER 3 U.S. CANNABINOIDS MARKET VARIABLES, TRENDS & SCOPE
3.1 Penetration And Growth Prospect Mapping
3.2 Cannabis and Cannabinoids Regulatory Framework in the U.S.
3.3 U.S. Cannabinoids Market Dynamics
3.3.1 Market Driver Analysis
3.3.2 Market Restraint Analysis
3.4 U.S. Cannabinoids Market Analysis Tools
3.4.1 Industry Analysis - Porter’s
3.4.1.1 Bargaining Power Of The Suppliers
3.4.1.2 Bargaining Power Of The Buyers
3.4.1.3 Threats Of Substitution
3.4.1.4 Threats From New Entrants
3.4.1.5 Competitive Rivalry
3.4.2 PESTLE Analysis
3.4.2.1 Political Landscape
3.4.2.2 Economic Landscape
3.4.2.3 Social Landscape
3.4.2.4 Technological Landscape
3.4.2.5 Environmental Landscape
3.4.2.6 Legal Landscape
3.5 Major Deals & Strategic Alliances Analysis
3.6 Opportunity Analysis (2016-2021-2030)
3.7 Supply Chain Analysis
3.8 Impact of COVID-19 on U.S. Cannabinoids Market
CHAPTER 4 U.S. CANNABINOIDS MARKET: COMPETITIVE LANDSCAPE ANALYSIS
4.1 Recent Developments & Impact Analysis, By Key Market Participants
4.2 Company/Competition Categorization (Key Innovators, Market Leaders, Emerging Players)
4.3 Company Market Position Analysis
CHAPTER 5 U.S. CANNABINOIDS MARKET: PRODUCT ESTIMATES & TREND ANALYSIS
5.1 U.S. Cannabinoids Market: Product Movement Analysis, USD Million, 2021 & 2030
5.2 Tetrahydrocannabinol (THC)
5.2.1 Tetrahydrocannabinol (THC) Market Estimates And Forecasts, 2016 - 2030 (USD Million)
5.3 Cannabidiol (CBD)
5.3.1 Cannabidiol (CBD) Market Estimates And Forecasts, 2016 - 2030 (USD Million)
5.4 Cannabigerol (CBG)
5.4.1 Cannabigerol (CBG) Market Estimates And Forecasts, 2016 - 2030 (USD Million)
5.5 Cannabichromene (CBC)
5.5.1 Cannabichromene (CBC) Market Estimates And Forecasts, 2016 - 2030 (USD Million)
5.6 Cannabinol (CBN)
5.6.1 Cannabinol (CBN) Market Estimates And Forecasts, 2016 - 2030 (USD Million)
5.7 Tetrahydrocannabivarin (THCV)
5.7.1 Tetrahydrocannabivarin (THCV) Market Estimates And Forecasts, 2016 - 2030 (USD Million)
5.8 Cannabigerolic acid (CBGA)
5.8.1 Cannabigerolic acid (CBGA) Market Estimates And Forecasts, 2016 - 2030 (USD Million)
5.9 Others
5.9.1 Others Market Estimates And Forecasts, 2016 - 2030 (USD Million)
CHAPTER 6 COMPANY PROFILES
6.1 Mile High Labs International
6.1.1 Company overview
6.1.2 Financial performance
6.1.3 Product benchmarking
6.1.4 Strategic initiatives
6.2 Global Cannabinoids
6.2.1 Company overview
6.2.2 Financial performance
6.2.3 Product benchmarking
6.2.4 Strategic initiatives
6.3 GenCanna
6.3.1 Company overview
6.3.2 Financial performance
6.3.3 Product benchmarking
6.3.4 Strategic initiatives
6.4 CBD INC
6.4.1 Company overview
6.4.2 Financial performance
6.4.3 Product benchmarking
6.4.4 Strategic initiatives
6.5 Precision Plant Molecules
6.5.1 Company overview
6.5.2 Financial performance
6.5.3 Product benchmarking
6.5.4 Strategic initiatives
6.6 Rhizo Sciences
6.6.1 Company overview
6.6.2 Financial performance
6.6.3 Product benchmarking
6.6.4 Strategic initiatives
6.7 LaurelCrest
6.7.1 Company overview
6.7.2 Financial performance
6.7.3 Product benchmarking
6.7.4 Strategic initiatives
6.8 Fresh Bros Hemp Company
6.8.1 Company overview
6.8.2 Financial performance
6.8.3 Product benchmarking
6.8.4 Strategic initiatives
6.9 BulKanna
6.9.1 Company overview
6.9.2 Financial performance
6.9.3 Product benchmarking
6.9.4 Strategic initiatives
6.10 High Purity Natural Products
6.10.1 Company overview
6.10.2 Financial performance
6.10.3 Product benchmarking
6.10.4 Strategic initiatives
6.11 Zero Point Extraction
6.11.1 Company overview
6.11.2 Financial performance
6.11.3 Product benchmarking
6.11.4 Strategic initiatives
6.12 List of Other Companies
1.1 Market Segmentation and Scope
1.2 Market Definition
1.3 Research Methodology
1.3.1 Information Procurement
1.3.1.1 Purchased Database
1.3.1.2 Gvr’s Internal Database
1.3.2 Primary Research
1.4 Research Scope And Assumptions
1.5 List To Data Sources
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Market Outlook
CHAPTER 3 U.S. CANNABINOIDS MARKET VARIABLES, TRENDS & SCOPE
3.1 Penetration And Growth Prospect Mapping
3.2 Cannabis and Cannabinoids Regulatory Framework in the U.S.
3.3 U.S. Cannabinoids Market Dynamics
3.3.1 Market Driver Analysis
3.3.2 Market Restraint Analysis
3.4 U.S. Cannabinoids Market Analysis Tools
3.4.1 Industry Analysis - Porter’s
3.4.1.1 Bargaining Power Of The Suppliers
3.4.1.2 Bargaining Power Of The Buyers
3.4.1.3 Threats Of Substitution
3.4.1.4 Threats From New Entrants
3.4.1.5 Competitive Rivalry
3.4.2 PESTLE Analysis
3.4.2.1 Political Landscape
3.4.2.2 Economic Landscape
3.4.2.3 Social Landscape
3.4.2.4 Technological Landscape
3.4.2.5 Environmental Landscape
3.4.2.6 Legal Landscape
3.5 Major Deals & Strategic Alliances Analysis
3.6 Opportunity Analysis (2016-2021-2030)
3.7 Supply Chain Analysis
3.8 Impact of COVID-19 on U.S. Cannabinoids Market
CHAPTER 4 U.S. CANNABINOIDS MARKET: COMPETITIVE LANDSCAPE ANALYSIS
4.1 Recent Developments & Impact Analysis, By Key Market Participants
4.2 Company/Competition Categorization (Key Innovators, Market Leaders, Emerging Players)
4.3 Company Market Position Analysis
CHAPTER 5 U.S. CANNABINOIDS MARKET: PRODUCT ESTIMATES & TREND ANALYSIS
5.1 U.S. Cannabinoids Market: Product Movement Analysis, USD Million, 2021 & 2030
5.2 Tetrahydrocannabinol (THC)
5.2.1 Tetrahydrocannabinol (THC) Market Estimates And Forecasts, 2016 - 2030 (USD Million)
5.3 Cannabidiol (CBD)
5.3.1 Cannabidiol (CBD) Market Estimates And Forecasts, 2016 - 2030 (USD Million)
5.4 Cannabigerol (CBG)
5.4.1 Cannabigerol (CBG) Market Estimates And Forecasts, 2016 - 2030 (USD Million)
5.5 Cannabichromene (CBC)
5.5.1 Cannabichromene (CBC) Market Estimates And Forecasts, 2016 - 2030 (USD Million)
5.6 Cannabinol (CBN)
5.6.1 Cannabinol (CBN) Market Estimates And Forecasts, 2016 - 2030 (USD Million)
5.7 Tetrahydrocannabivarin (THCV)
5.7.1 Tetrahydrocannabivarin (THCV) Market Estimates And Forecasts, 2016 - 2030 (USD Million)
5.8 Cannabigerolic acid (CBGA)
5.8.1 Cannabigerolic acid (CBGA) Market Estimates And Forecasts, 2016 - 2030 (USD Million)
5.9 Others
5.9.1 Others Market Estimates And Forecasts, 2016 - 2030 (USD Million)
CHAPTER 6 COMPANY PROFILES
6.1 Mile High Labs International
6.1.1 Company overview
6.1.2 Financial performance
6.1.3 Product benchmarking
6.1.4 Strategic initiatives
6.2 Global Cannabinoids
6.2.1 Company overview
6.2.2 Financial performance
6.2.3 Product benchmarking
6.2.4 Strategic initiatives
6.3 GenCanna
6.3.1 Company overview
6.3.2 Financial performance
6.3.3 Product benchmarking
6.3.4 Strategic initiatives
6.4 CBD INC
6.4.1 Company overview
6.4.2 Financial performance
6.4.3 Product benchmarking
6.4.4 Strategic initiatives
6.5 Precision Plant Molecules
6.5.1 Company overview
6.5.2 Financial performance
6.5.3 Product benchmarking
6.5.4 Strategic initiatives
6.6 Rhizo Sciences
6.6.1 Company overview
6.6.2 Financial performance
6.6.3 Product benchmarking
6.6.4 Strategic initiatives
6.7 LaurelCrest
6.7.1 Company overview
6.7.2 Financial performance
6.7.3 Product benchmarking
6.7.4 Strategic initiatives
6.8 Fresh Bros Hemp Company
6.8.1 Company overview
6.8.2 Financial performance
6.8.3 Product benchmarking
6.8.4 Strategic initiatives
6.9 BulKanna
6.9.1 Company overview
6.9.2 Financial performance
6.9.3 Product benchmarking
6.9.4 Strategic initiatives
6.10 High Purity Natural Products
6.10.1 Company overview
6.10.2 Financial performance
6.10.3 Product benchmarking
6.10.4 Strategic initiatives
6.11 Zero Point Extraction
6.11.1 Company overview
6.11.2 Financial performance
6.11.3 Product benchmarking
6.11.4 Strategic initiatives
6.12 List of Other Companies
LIST OF TABLES
Table 1 Partial list of secondary sources
Table 1 Partial list of secondary sources
LIST OF FIGURES
Fig. 1 U.S. Cannabinoids market segmentation
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 U.S. Cannabinoids market snapshot, 2021 (USD Million)
Fig. 10 Penetration & growth prospects mapping
Fig. 11 U.S. Cannabinoids market dynamics
Fig. 12 U.S. Cannabinoids market driver impact
Fig. 13 U.S. Cannabinoids market restraints impact
Fig. 14 U.S. Cannabinoids market - PESTLE analysis
Fig. 15 U.S. Cannabinoids market - Porter’s Analysis
Fig. 16 Opportunity analysis (2016-2021-2030)
Fig. 17 Recent Developments & Impact Analysis, By Key Market Participants
Fig. 18 Company Market Position Analysis
Fig. 19 U.S. Cannabinoids market, Product outlook: Key takeaways
Fig. 20 U.S. Cannabinoids market: Product movement analysis (2021 & 2030) (USD Million)
Fig. 21 Tetrahydrocannabinol (THC) market estimates and forecasts, 2016 - 2030 (USD Million)
Fig. 22 Cannabidiol (CBD) market estimates and forecasts, 2016 - 2030 (USD Million)
Fig. 23 Cannabigerol (CBG) market estimates and forecasts, 2016 - 2030 (USD Million)
Fig. 24 Cannabichromene (CBC) market estimates and forecasts, 2016 - 2030 (USD Million)
Fig. 25 Cannabinol (CBN) market estimates and forecasts, 2016 - 2030 (USD Million)
Fig. 26 Tetrahydrocannabivarin (THCV) market estimates and forecasts, 2016 - 2030 (USD Million)
Fig. 27 Cannabigerolic acid (CBGA) market estimates and forecasts, 2016 - 2030 (USD Million)
Fig. 28 Other minor cannabinoids market estimates and forecasts, 2016 - 2030 (USD Million)
Fig. 1 U.S. Cannabinoids market segmentation
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 U.S. Cannabinoids market snapshot, 2021 (USD Million)
Fig. 10 Penetration & growth prospects mapping
Fig. 11 U.S. Cannabinoids market dynamics
Fig. 12 U.S. Cannabinoids market driver impact
Fig. 13 U.S. Cannabinoids market restraints impact
Fig. 14 U.S. Cannabinoids market - PESTLE analysis
Fig. 15 U.S. Cannabinoids market - Porter’s Analysis
Fig. 16 Opportunity analysis (2016-2021-2030)
Fig. 17 Recent Developments & Impact Analysis, By Key Market Participants
Fig. 18 Company Market Position Analysis
Fig. 19 U.S. Cannabinoids market, Product outlook: Key takeaways
Fig. 20 U.S. Cannabinoids market: Product movement analysis (2021 & 2030) (USD Million)
Fig. 21 Tetrahydrocannabinol (THC) market estimates and forecasts, 2016 - 2030 (USD Million)
Fig. 22 Cannabidiol (CBD) market estimates and forecasts, 2016 - 2030 (USD Million)
Fig. 23 Cannabigerol (CBG) market estimates and forecasts, 2016 - 2030 (USD Million)
Fig. 24 Cannabichromene (CBC) market estimates and forecasts, 2016 - 2030 (USD Million)
Fig. 25 Cannabinol (CBN) market estimates and forecasts, 2016 - 2030 (USD Million)
Fig. 26 Tetrahydrocannabivarin (THCV) market estimates and forecasts, 2016 - 2030 (USD Million)
Fig. 27 Cannabigerolic acid (CBGA) market estimates and forecasts, 2016 - 2030 (USD Million)
Fig. 28 Other minor cannabinoids market estimates and forecasts, 2016 - 2030 (USD Million)
